Roche’s Spring Bioscience introduces PD-L1 IHC antibody for immunotherapy research

PD-L1 (SP142) rabbit monoclonal antibody is for research use only (RUO) and has been developed for Roche/Genentech’s anti-PD-L1 (MPDL3280A) immunotherapy development program as well as in research of various tumor types.

According to the internal comparison studies carried out at the company, the PD-L1 (SP142) antibody outperformed other commercially available PD-L1 antibodies.

SP142 meets the company’s standards as a tool to assess PD-L1 expression in many different tumor types.

Spring Biosience general manager Michael Rivers said: "As with all IHC antibodies developed by Spring, the SP142 antibody will deliver the high quality and accuracy that clinical researchers need to confidently assess PD-L1 status in tissue samples."

Ventana Companion Diagnostics vice-president and Lifecycle Leader Doug Ward said the development of the PD-L1 (SP142) antibody was designed to be very sensitive and specific.

"As researchers strive to understand the clinical relevance of PD-L1 expression, this clone may offer a superior ability to stain and analyze both tumor and immune cells," Ward said.

"Ventana and Spring are committed to delivering gold standard biomarker detection solutions for companion diagnostic tests."